Admission open for Online Programs - We wish you take the first step towards building a better and a bright future by enrolling in our Undergraduate and Postgraduate Programs!
university of mysore

Dr Basappa’s laboratory at the University of Mysore has developed a new breast cancer drug-like compound (oxadiazole-based PARP inhibitors). The newly developed oxadiazole-based PARP inhibitors are for treating advanced breast cancer patients.
Breast cancer occurs most commonly in women and is the second most common worldwide. According to WHO (World Health Organisation), in 2020, there were 2.3 million women diagnosed with it, and 685000 humans died due to it globally.
The disease progresses through stages which the doctors describe as the TNM system — Tumour (T), Node (N), and Metastasis (M). If a patient dies of breast cancer, it happens because of its spread (metastasis), the advanced stage. At the situ (stage 0), it may progress and invade the surrounding breast tissues and spread to the nearby lymph nodes or other organs in the body.
The newly developed "oxadiazole-based PARP inhibitor" restrains the viability of human breast cancer cells with an IC50 value of 1.4 micromolar compared to Olaparib (3.2 micromolar) that came earlier. The new invention holds hopes for patients with breast cancer with advanced stages.
Dr Basappa, faculty at the "Department of Studies in Organic Chemistry" and also a "Deputy Registrar-Administration", University of Mysore (UoM), is a student of former UoM VC Prof. K.S. Rangappa. Prof. K.S. Rangappa, CSIR Professor-Emeritus at the University, is also involved in this discovery.
The research fraternity reveals that the newly discovered (5u) PARP inhibitors serve as an exemplar for the evolution of new therapeutics in breast cancer.